Physician profile
Kathryn E Cameron
NPI 1700877081
$2,368.91
in general payments reported to CMS, 2019-2025
21 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $48.12 · 2024: $166 · 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.97 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $546.84 | 2025 | Tezspire, Fasenra, Breztri |
| Amgen INC. | $284.42 | 2025 | Tezspire |
| Inspire Medical Systems, INC. | $226.32 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $214.63 | 2025 | Dupixent |
| Boston Scientific Corporation | $211.77 | 2025 | Ams 700 |
| Glaxosmithkline, LLC. | $185.51 | 2025 | Trelegy Ellipta, Nucala |
| 3b Medical, INC. | $94.76 | 2025 | Luna |
| Insmed, INC. | $79.51 | 2025 | Arikayce |
| Viatris Specialty LLC | $71.74 | 2025 | Yupelri |
| Verona Pharma, INC. | $63.96 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $60.74 | 2025 | |
| Davol INC. | $48.12 | 2023 | Phasix Mesh |
| United Therapeutics Corporation | $40.62 | 2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.51 | 2025 | Jascayd |
| Vifor Pharma, INC. | $33.81 | 2025 | Zemaira |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $33.01 | 2025 | |
| Genzyme Corporation | $32.48 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $32.43 | 2025 | Lumryz |
| Resmed Corp | $29.50 | 2025 | |
| Axsome Therapeutics, INC. | $24.35 | 2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $13.88 | 2025 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.